Table 3.

Pharmacokinetic data of AT following single oral administration (25 mg/kg) of NLC-1, AT suspension and commercial tablet to rats.

Pharmacokinetic parameters	NLC-1	AT suspension	Lipitor®
Cmax (μg/ml)	25 ± 1.4a	9.7 ± 1.5	11.9 ± 1.3
Tmax (hr)	2 ± 0.25a	1.5 ± 0.15	1.5
AUC0–∞ (μgahr/ml)	599 ± 224.3a	168.1 ± 27	286.3 ± 38.5
AUC0–24 (μgahr/ml)	370.9 ± 65a	101.8 ± 2.7	129.3 ± 3.7
Relative bioavailability		3.56	2.09

Each value expressed as the mean ± SD (n = 3).

^a Significant at p < .05.